Loading
A phase 3 trial of Cyclophosphamide, Doxorubicin, Prednisone and Vincristine in non-Hodgkin lymphoma, run by Chipscreen Biosciences, Ltd., now recruiting.
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype is a phase 3 interventional study registered as NCT06947967 by Chipscreen Biosciences, Ltd., with 224 participants planned, started 2025-08-12 and due to reach its primary completion in 2032-12. Interventions recorded: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone), Tucidinostat and Placebo.
Shares Prednisone, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Vincristine, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Vincristine, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Vincristine, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Vincristine, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Vincristine, Doxorubicin, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Prednisone, Vincristine, Doxorubicin, Cyclophosphamide and the tag pipeline.